POLAREAN IMAGING PLC

AGM Information • Jul 13, 2020

National Storage Mechanism | Additional information

RNS Number : 8546S

Polarean Imaging PLC

13 July 2020

Polarean Imaging Plc 

("Polarean" or the "Company")

Result of AGM

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that at the AGM held earlier today, all resolutions were duly passed.   

Details of the proxy votes received on each resolution by Polarean's Registrar are set out below:

Resolution	For	Against
Resolution 1	69,040,651	0
Resolution 2	69,035,550	5,101
Resolution 3	69,040,651	0
Resolution 4	69,040,651	0
Resolution 5	69,040,651	0
Resolution 6	69,040,651	0
Resolution 7	69,010,651	0
Resolution 8	68,885,651	125,000

Contacts:

Polarean Imaging plc	www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer  Jonathan Allis, Chairman	Via Walbrook PR
SP Angel Corporate Finance LLP Nomad and Broker			Tel: +44 (0)20 3470 0470
David Hignell / Soltan Tagiev (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR	Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy	Mob: +44 (0)7980 541 893 / +44 (0)7876 741 001

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical drug-device combination companies operating in the high-resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarized Xenon gas (129Xe) as an imaging agent to visualize ventilation.129Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung, and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging 129Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimize the imaging of 129Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGSFSFDDESSEEW